ArticleMicrobiome2025
Modulating the developing gut microbiota with 2'-fucosyllactose and pooled human milk oligosaccharides.
Article in Microbiome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- 2'-FL's Depiction of the Human Physiological Function Landscape.Food science & nutrition · 2026Review
- Current Perspective on Human Milk Derived Vesicles and Their Potential Therapeutic Use: A Scoping Review.Journal of extracellular vesicles · 2026Article
- Clostridia from preterm infants metabolize human milk oligosaccharides to suppress pathobionts and modulate intestinal function in organoids.Nature microbiology · 2026Article
- Limited Evidence of Benefits from Clinical Trials of Human-Identical Milk Oligosaccharides for Infants.Advances in nutrition (Bethesda, Md.) · 2026Review
- The impact of human milk oligosaccharides and galacto-oligosaccharides on the growth of early life pathogenic gut bacteria.Frontiers in microbiology · 2026Article
- 2'-Fucosyllactose and its metabolites propionate/butyrate suppress inflammation through a shared TLR4/p38 MAPK-dependent pathwayCurrent research in food science · 2026Article
- Environmental and maternal imprints on infant gut metabolic development.Cell host & microbe · 2025Article
- Article
- Human milk oligosaccharide metabolism and antibiotic resistance in early gut colonizers: insights from bifidobacteria and lactobacilli in the maternal-infant microbiome.Gut microbes · 2025Article
- The microbiome's hidden influence: preclinical insights into inflammatory responses in necrotizing enterocolitis.Seminars in immunopathology · 2025Review
- Human gut prophage landscape identifies a prophage-mediated fucosylation mechanism alleviating colitis.Nature communications · 2025Article
- Integrative genomic reconstruction reveals heterogeneity in carbohydrate utilization across human gut bifidobacteria.Nature microbiology · 2025Article
- Environmental and Maternal Imprints on Infant Gut Metabolic Programming.bioRxiv : the preprint server for biology · 2025Article
- Bifidobacterium deficit in United States infants drives prevalent gut dysbiosis.Communications biology · 2025Article
- Integrative genomic reconstruction reveals heterogeneity in carbohydrate utilization across human gut bifidobacteria.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSynthetic human milk oligosaccharides (HMOs) are used to supplement infant formula despite limited understanding of their impact on the post-weaned developing gut microbiota. Here, we assess the influence of 0.5 g/L 2-fucosyllactose (2'FL) and 4.0 g/L pooled HMOs (pHMOs) on the composition and activity of cultured fecal-derived microbial communities from seven healthy young children.
resultsExposure to pHMOs induced significant shifts in both the microbial community composition and metabolic output, including an increased abundance of several genera, notably Bacteroides, and the production of health-associated metabolites. In contrast, 2'FL alone did not lead to substantial changes in the communities. A total of 330 bacterial isolates, spanning 157 species, were cultured from these communities and individually evaluated for their responses to HMOs. Over 100 non-Bifidobacterium species showed enhanced growth upon pHMOs treatment and a high degree of intraspecies variation in HMO metabolism was observed.
conclusionOur study provides valuable insight into the health-enhancing properties of HMOs while highlighting the need for future research into the efficacy of incorporating individual structures into infant formula, particularly when aiming to modulate the gut microbiota. Video Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.